Literature DB >> 25342979

Isoniazid in autoimmunity: a trigger for multiple sclerosis?

Bardia Nourbakhsh1, Olaf Stüve2.   

Abstract

Isoniazid (INH) is a prodrug activated by the mycobacterial enzyme KatG, a multifunctional catalase peroxidase. KatG converts INH to reactive antimycobacterial species. For decades, an association between INH and drug-induced lupus erythematosus has been recognized. We present the case of a patient with primary progressive multiple sclerosis whose disease commenced weeks after initiating INH therapy for prevention of tuberculosis. Possible mechanisms by which INH may trigger autoimmunity in humans are discussed.

Entities:  

Keywords:  Autoimmunity; Isoniazid; Multiple Sclerosis

Year:  2014        PMID： 25342979      PMCID： PMC4206619          DOI： 10.1177/1756285614540361

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN： 1756-2856            Impact factor:   6.570


  15 in total

Review 1.  Drug-induced lupus erythematosus: incidence, management and prevention.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

Review 2.  Multiple sclerosis--the plaque and its pathogenesis.

Authors:  Elliot M Frohman; Michael K Racke; Cedric S Raine
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

3.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

Review 4.  Drug-induced lupus: an update.

Authors:  S Vasoo
Journal:  Lupus       Date:  2006       Impact factor: 2.911

5.  Studies on immunomodulatory properties of isoniazid. I. Effect of isoniazid on mitogen- and anti-CD3 antibody-induced proliferation of human peripheral blood mononuclear cells and T cells.

Authors:  E J Kucharz; S J Sierakowski
Journal:  J Hyg Epidemiol Microbiol Immunol       Date:  1990

6.  IgA antihistone antibodies in isoniazid-treated tuberculosis patients.

Authors:  M Vázquez-Del Mercado; C A Casiano; R L Rubin
Journal:  Autoimmunity       Date:  1995       Impact factor: 2.815

Review 7.  Demyelination and other neurological adverse events after anti-TNF therapy.

Authors:  Evripidis Kaltsonoudis; Paraskevi V Voulgari; Spyridon Konitsiotis; Alexandros A Drosos
Journal:  Autoimmun Rev       Date:  2013-09-12       Impact factor: 9.754

8.  Treatment of action tremor in multiple sclerosis with isoniazid.

Authors:  A F Sabra; M Hallett; L Sudarsky; W Mullally
Journal:  Neurology       Date:  1982-08       Impact factor: 9.910

9.  Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group.

Authors:  J L Haines; H A Terwedow; K Burgess; M A Pericak-Vance; J B Rimmler; E R Martin; J R Oksenberg; R Lincoln; D Y Zhang; D R Banatao; N Gatto; D E Goodkin; S L Hauser
Journal:  Hum Mol Genet       Date:  1998-08       Impact factor: 6.150

10.  Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.

Authors:  Sung R Choi; Owain W Howell; Daniele Carassiti; Roberta Magliozzi; Djordje Gveric; Paolo A Muraro; Richard Nicholas; Federico Roncaroli; Richard Reynolds
Journal:  Brain       Date:  2012-08-20       Impact factor: 13.501
View more
  1 in total

1.  Toll-Like Receptor 2 Mediates In Vivo Pro- and Anti-inflammatory Effects of Mycobacterium Tuberculosis and Modulates Autoimmune Encephalomyelitis.

Authors:  Alessia Piermattei; Giuseppe Migliara; Gabriele Di Sante; Maria Foti; Soren Bohos Hayrabedyan; Angela Papagna; Maria Concetta Geloso; Maddalena Corbi; Mariagrazia Valentini; Alessandro Sgambato; Giovanni Delogu; Gabriela Constantin; Francesco Ria
Journal:  Front Immunol       Date:  2016-05-24       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.